Jack Wallace
Stock Analyst at Guggenheim
(2.86)
# 1,687
Out of 4,876 analysts
19
Total ratings
62.5%
Success rate
23.5%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $283.41 | -12.14% | 4 | Oct 1, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $49.41 | -65.59% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $3.81 | +267.45% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $157.47 | +39.71% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $28.44 | +40.65% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $7.94 | +1,159.45% | 1 | Mar 15, 2023 | |
| PINC Premier | Initiates: Neutral | n/a | $21.61 | - | 1 | Apr 14, 2022 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $283.41
Upside: -12.14%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $49.41
Upside: -65.59%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $3.81
Upside: +267.45%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $157.47
Upside: +39.71%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $28.44
Upside: +40.65%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $7.94
Upside: +1,159.45%
Premier
Apr 14, 2022
Initiates: Neutral
Price Target: n/a
Current: $21.61
Upside: -